Wednesday, February 10, 2010, 9:08am EST - Canadian Markets open in 22 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Cell Therapeutics, Inc. (CTIC)

 On Feb 9: 0.7735 USD   0.00 (0.00%)  
MORE ON CTIC
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Cell Therapeutics, Inc. (NCM:CTIC) Delayed quote dataEdit
Pre-Market: 0.75 Down 0.0235 (3.04%) as of 8:52am EST on 02/10/10
Last Trade: 0.7735 USD
Trade Time: Feb 9
Change: 0.00 (0.00%)
Prev Close: 0.7735
Open: N/A
Bid: 0.7501 x 2000
Ask: 0.76 x 30000
1y Target Est: 2.00
Day's Range: N/A - N/A
52wk Range: 0.05 - 2.23
Volume: 297,066
Avg Vol (3m): 14,618,700
Market Cap: 444.32M
P/E (ttm): N/A
EPS (ttm): -0.39
Div & Yield: N/A (N/A%)
Cell Therapeutics, Inc. (CTIC)
1d  5d  3m  6m  1y  2y  5y  max 
 Add CTIC to Portfolio   Download Data

HEADLINES
• Equities Update: Greece Rumors Lift Stocks
at Seeking Alpha (Tue 4:32pm)
• FDA Agreements Should Be Public
at Forbes.com (Tue 4:23pm)
• Biggest changes in Nasdaq short interest
at Reuters (Tue 4:18pm)
• Biotech Stocks: Cell Therapeutics, AstraZeneca lead drug stocks
at MarketWatch (Tue 1:31pm)
• Biotech Stocks: Drug stocks gain; Cell Therapeutics rebounds
at MarketWatch (Tue 10:23am)
• CELL THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
EDGAR Online (Tue 6:06am)
• FDA Postpones Oncologic Drugs Advisory Committee Meeting to Review Pixantrone Due to Severe Weather Conditions
PRNewswire (Tue 1:30am)
• Cell Therapeutics Panel Cancelled Because Of Snow
at Forbes.com (Mon, Feb 8)
• UPDATE - Cell Therapeutics drug draws US FDA staff concerns
at Reuters (Mon, Feb 8)
• Cell Therapeutics Lymphoma Drug Faces FDA Questioning
at Fox Business (Mon, Feb 8)
• Cell Therapeutics’ Last Hope for Survival, Dashed
at Minyanville.com (Mon, Feb 8)
More Headlines for CTIC...
ANALYST
EPS Est (next year) (Dec-09) : -0.24
EPS Est (in 2 years) (Dec-10) : -0.08
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Cell Therapeutics, Inc., a biopharmaceutical company, develops, acquires, and commercializes oncology products for cancer treatment. Its development portfolio includes Pixantrone, a phase III trial product, for non-Hodgkin’s lymphoma; Brostal...

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices